News Sentiment

ACOG sentiment intelligence

Alpha Cognition Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.41 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+6.6% over one week, +40.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Raymond James Starts Alpha Cognition (ACOG) at Outperform

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 6.6% Price confirming higher
Trend fit Trend active 40.4% over four weeks
Fair value 25.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 28
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 6
Business Wire 3
MT Newswires 3
Investing.com Nigeria 2
Moomoo 2
The Globe and Mail 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 20
Analyst action 5
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Investing.com Nigeria Direct company coverage

Raymond James initiates Alpha Cognition stock coverage with outperform rating

Raymond James has initiated coverage of Alpha Cognition Inc. (NASDAQ: ACOG) with an Outperform rating and a $20.00 price target, highlighting the potential of its Alzheimer's drug Zunveyl. The stock is currently trading below the consensus target, with InvestingPro data suggestin

Tone
Positive 73/100
Event
Analyst action
Published
11 Jul 2026 00:09
Source
Investing.com Nigeria
Moomoo Direct company coverage

Alpha Cognition Initiated at Outperform by Raymond James

Raymond James has initiated coverage on Alpha Cognition (NASDAQ: ACOGF) with an "Outperform" rating. This news suggests a positive outlook from the financial firm regarding the company's future performance.

Tone
Positive 75/100
Event
Analyst action
Published
10 Jul 2026 13:13
Source
Moomoo
Business Wire Direct company coverage

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Alpha Cognition Inc. announced that its CEO, Michael McFadden, will participate in a Late-Stage & Commercial CNS Small Cap panel discussion at the B. Riley Securities Mind, Muscle & Vision Summit on July 16th in Boston. The company focuses on developing therapies for neurodegener

Tone
Positive 67/100
Event
Market update
Published
10 Jul 2026 12:39
Source
Business Wire
TradingView Direct company coverage

Price to sales forward of Alpha Cognition Inc. – NASDAQ:ACOG

This article provides financial data for Alpha Cognition Inc. (NASDAQ: ACOG), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a data point from a larger financial platform, offering a snapshot of the company's valuation metric. The content it

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 17:09
Source
TradingView
Finviz Direct company coverage

ACOG - Alpha Cognition Inc Latest SEC Filings

This article provides key financial data for Alpha Cognition Inc (ACOG), including its latest stock performance, market capitalization, income, sales, and employee count. It also details various financial ratios, insider and institutional ownership, profitability margins, and ana

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 16:39
Source
Finviz
TradingView Direct company coverage

Enterprise value to revenue forward of Alpha Cognition Inc. – NASDAQ:ACOG

This article focuses on the "Enterprise value to revenue forward" metric for Alpha Cognition Inc. (NASDAQ: ACOG). It appears to be a stub or a pre-filled template from TradingView, providing financial page structure without specific data points in the provided content. The articl

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 02:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Alpha Cognition Inc. – NASDAQ:ACOG

This article focuses on the "Enterprise value to EBIT forward" metric for Alpha Cognition Inc. (NASDAQ: ACOG). It presents this specific financial data point as part of the company's financial overview on TradingView. The content is primarily a data page, providing the metric wit

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 08:41
Source
TradingView
TradingView Direct company coverage

Alpha Cognition Inc Actuals & Estimates (NASDAQ:ACOG)

This article provides an overview of Alpha Cognition Inc. (NASDAQ: ACOG) financials and analyst estimates. It covers historical stock performance, price forecasts, earnings reports, revenue, market capitalization, and volatility, highlighting that ACOG does not pay dividends and

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

ACOG Forecast — Price Target — Prediction for 2027

This article provides an overview of Alpha Cognition Inc. (ACOG) stock, including analyst price targets, financial performance, and historical stock data. It summarizes current and predicted earnings per share and revenue, notes the stock's volatility and market capitalization, a

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 8K Alpha Cognition Inc. For: 23 June By Investing.com

This article is a brief announcement from Investing.com about Alpha Cognition Inc.'s Form 8K filing for June 23. It includes a stock price mention for ACOG and is primarily a placeholder for the SEC filing information. The content also features various market data, trending stock

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 05:41
Source
Investing.com Nigeria
The Globe and Mail Direct company coverage

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

Alpha Cognition Inc. announced that Dr. Robert Wills has been elected Chairman of its Board of Directors, succeeding Len Mertz. Dr. Wills brings extensive experience from his previous roles at Johnson & Johnson and various other pharmaceutical companies, and has been on Alpha Cog

Tone
Positive 72/100
Event
Market update
Published
23 Jun 2026 20:09
Source
The Globe and Mail
Investing.com Direct company coverage

Alpha Cognition names Robert Wills as board chairman

Alpha Cognition Inc. (NASDAQ:ACOG) has appointed Robert Wills as its new Chairman of the Board, replacing Len Mertz. Wills has extensive experience in the biopharmaceutical industry, previously serving on Alpha Cognition's board since 2025 and holding leadership roles at other co

Tone
Positive 75/100
Event
Market update
Published
23 Jun 2026 19:09
Source
Investing.com
citybiz Direct company coverage

Alpha Cognition Elects Biopharma Veteran Dr. Robert Wills as Board Chairman

Alpha Cognition Inc. has appointed biopharma veteran Dr. Robert Wills as the new chairman of its board of directors, succeeding Len Mertz. Dr. Wills brings extensive experience from Johnson & Johnson and various board leadership roles at other pharmaceutical companies, which will

Tone
Positive 70/100
Event
Market update
Published
23 Jun 2026 18:09
Source
citybiz
Minichart Direct company coverage

Alpha Cognition Inc. (ACOG) Files 8-K Announcing Officer Changes and Shareholder Voting Results – June 2026

Alpha Cognition Inc. (ACOG) has filed an 8-K report detailing the results of its recent shareholder meeting, including the election of six directors and the ratification of CBIZ CPAs P.C. as their independent registered public accounting firm. The company also confirmed its statu

Tone
Positive 61/100
Event
Earnings
Published
23 Jun 2026 15:40
Source
Minichart
Moomoo Direct company coverage

Press Release: Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Alpha Cognition (Nasdaq: ACOG) is scheduled to report its first quarter 2026 financial results on Thursday, May 14, 2026. The company will also provide a business update, likely covering advancements in its clinical programs or strategic initiatives. This announcement will be of

Tone
Neutral 50/100
Event
Earnings
Published
22 Jun 2026 05:12
Source
Moomoo
Proactive financial news Direct company coverage

Alpha Cognition Share Price - ACOGF, RNS News, Articles, Quotes, & Charts (OTCMKTS:ACOGF)

Alpha Cognition (OTCMKTS: ACOGF) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). Their product ALPHA-1062 is being developed for Alzheimer's, while ALP

Tone
Neutral 50/100
Event
Market update
Published
20 Jun 2026 15:41
Source
Proactive financial news
The Globe and Mail Direct company coverage

Craig-Hallum Keeps Their Buy Rating on Alpha Cognition Inc (ACOG)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Alpha Cognition Inc. (ACOG), with the company showing strong insider sentiment and a significant upside potential according to the average analyst price target. Despite reporting a GAAP net loss of $6.48 million

Tone
Positive 73/100
Event
Analyst action
Published
20 Jun 2026 04:09
Source
The Globe and Mail
Simply Wall Street Direct company coverage

Alpha Cognition Insiders Still US$88k Away From Original Investment Value

Insiders at Alpha Cognition (NASDAQ: ACOG) purchased US$397.5k worth of shares in the past year, but their investment is still down by US$88k, despite a recent 12% price gain. The largest purchase was by Independent Chairman Len Mertz for US$250k at US$9.00 per share, indicating

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:39
Source
Simply Wall Street
TradingKey Direct company coverage

Alpha Cognition Inc (ACOG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Alpha Cognition Inc (ACOG). It indicates that the company has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also presents current stock performance d

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 12:11
Source
TradingKey
Stock Titan Direct company coverage

Alzheimer’s drug ZUNVEYL to be tested in real-world use through Q2 2027

Alpha Cognition has enrolled the first patient in its RESOLVE Phase 4 post-marketing clinical study for ZUNVEYL, an FDA-approved Alzheimer's drug. This study aims to further evaluate the drug's tolerability and treatment experience in real-world clinical practice, collecting safe

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 02:40
Source
Stock Titan
BioSpace Direct company coverage

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease

Alpha Cognition has announced the enrollment of the first patient in its RESOLVE Phase 4 clinical study for ZUNVEYL®, a treatment for mild to moderate Alzheimer's disease. This post-marketing study aims to further assess the tolerability profile and treatment experience of ZUNVEY

Tone
Positive 76/100
Event
Market update
Published
16 Jun 2026 14:09
Source
BioSpace
Investing.com Direct company coverage

Alpha Cognition enrolls first patient in ZUNVEYL phase 4 study

Alpha Cognition Inc. has enrolled the first patient in its Phase 4 post-marketing clinical study, RESOLVE, for its FDA-approved Alzheimer's treatment, ZUNVEYL. This multicenter study will evaluate the tolerability and safety profile of ZUNVEYL in routine clinical practice for pat

Tone
Positive 73/100
Event
Market update
Published
16 Jun 2026 13:09
Source
Investing.com
Investing.com Canada Direct company coverage

Alpha Cognition enrolls first patient in ZUNVEYL phase 4 study By Investing.com

Alpha Cognition Inc. has enrolled the first patient in its Phase 4 clinical study, RESOLVE, for ZUNVEYL, an FDA-approved treatment for mild to moderate Alzheimer’s disease. The study aims to evaluate ZUNVEYL's tolerability in routine clinical practice and monitor safety, treatmen

Tone
Positive 65/100
Event
Market update
Published
16 Jun 2026 13:02
Source
Investing.com Canada